BACKGROUND
The progress of medical care and health services research increasingly depends upon combining different types, sources, and volumes of data efficiently. Specific plans to apply "big data" solutions to produce individually tailored clinical decision support (CDS) for a patient at the point of care necessitate overcoming obstacles that arise from the different ways that data are collected and coded into electronic systems. Thus, it is not just a matter of data scale but also a matter of reaching agreements on how these data are represented and accessed. Without such standards, the ability of both researchers and developers to create tools that make the best use of such valuable data is severely limited.
The development of quick and cost-efficient DNA sequencing techniques has led to a dramatic growth in the volume of human genome sequencing data. 1 Genomics data are considered to be large and unwieldy, which explains why several conflicting systems for data management and storage already exist. Most genomic data systems offer application protocol interfaces (APIs) that reflect their underlying data storage formats. For example, Illumina, Inc. offers variant APIs (in their Basespace product) that map directly to the Variant Call Format (VCF). There are obvious benefits to this arrangement when data is being used for research. In particular, researchers maintain compatibility with software operating on raw data files. Other proprietary APIs include those of GenoSpace, LLC and Seven Bridges Genomics, Inc. These APIs focus on operating on genomic data stored in a cloud. Another example that is focused on communicating genomic information in the cloud is the Global Alliance for Genomics and Health (GA4GH). Rather than a proprietary API controlled by a single company, GA4GH brought together a number of stakeholders, including Substitutable Medical Applications & Reusable Technologies (SMART) on Fast Health Interoperability Resource (FHIR) Genomics. In the clinical genomics field, a previous effort by Health Level Seven International (HL7 V R ) involved communicating variants, in a message format, between the electronic health records (EHRs) of Partners V R HealthCare and Intermountain HealthCare in a demonstration project. It can be argued that genomic information may not be suitable for the message format used by HL7. New web technologies, such as Representational State Transfer (REST)-based APIs/web services, have recently been adopted by HL7 and hold great promise in this regard. In addition, authentication and user interface issues need to be standardized. Finally, it may be that a simpler, developer-centric approach is needed for wider adoption of clinicogenomic standards, as has been the focus of SMART V R . 2, 3 For application developers and clinicians, creating an abstraction layer above specific file formats offers important advantages. First, although the tools and technology of DNA sequencing continue to progress rapidly and develop divergences in what is stored within sequencing systems, gene and variant data will likely continue to be used in clinical applications. Second, an API that directly maps to sequencing files may involve unnecessary details (eg, sequence alignment), which are not used by the majority of developers and clinicians. Conflicting vendor approaches pose challenges to end-users, including physicians, caregivers, patients, and medical researchers, and developers, who must build solutions to work with genomics data across multiple formats or else forego valuable data. 4, 5 It is unsurprising that both of these groups would like some form of data standardization to succeed. 6 However, data standardization may not always fit the technical needs of a rapidly evolving discipline, and, even if they do, adoption of standardization measures typically requires extensive work with an uncertain payoff. Third, an API needs to be linked to a standards organization, which creates standards that are and will be used by EHR vendors, clinicians, and government mandates (eg, Meaningful Use Stage 3). Finally, the API should be able to fully contextualize genomics information with other clinical data for clinical care, subsequent outcomes analysis, and discovery research. To encourage adoption of genomics standards, SMART on FHIR Genomics has been conceived by extending SMART on FHIR. SMART on FHIR emerged from the combination of the SMART Platform project 2, 3 and the HL7 V R FHIR V R effort. 7 SMART on FHIR combines FHIR-compliant clinical data access from EHR systems with web standards to launch web and mobile apps from a user's EHR session, including FHIR's REST-based API for clinical data, OAuth 2.0 authentication, and HTML5 to support web and native mobile apps. 3 
METHODS
SMART on FHIR Genomics specifies genomic variant data resource definitions to support the development of clinico-genomic apps. Data can be sourced from EHR systems or separate sequencing systems. Genomic data systems that comply with SMART on FHIR Genomics will be able to field data queries and return variant data results predictably, irrespective of their internal approach to data storage. The key effort for a data provider is simply to implement a SMART on FHIR Genomics data adaptor, which creates a binding to convert between the standard SMART on FHIR Genomics format and the provider's native format.
We created the SMART on FHIR Genomics specification by building on top of a large set of existing technologies, consistent with the FHIR ideal to provide a codeable concept for any given data element without "reinventing the wheel." For genomic data nomenclature, we adopted: the systematized Nomenclature of Medicine, Clinical Terms, for diseases and qualifier values; the Human Genome Variation Society mutnomen syntax, for mutation names and locations; 8 the Consensus Coding Sequence representation, for genomic regions; 9 and the Human Genome Organization Gene Nomenclature Committee (HGNC a.k.a. HUGO) symbols and identifiers, for common gene names. 10 For representing queries and returning structured payloads of standards-coded clinical genomics data, we provide definitions based on the initial FHIR Draft Standard for Trial Use (DSTU1). FHIR adopts contemporary web technology that is convenient both for data providers and consumers.
11 SMART on FHIR uses FHIR's profiling feature to lock down nomenclature requirements for consistent semantics in clinical data. SMART on FHIR Genomics leverages FHIR's formal mechanism for resource extension to handle multiple types of clinical genomics data, including: wrappers for genomic data files (eg, VCFs), messaging services for genomic lab results, and document services for interpretative genomic reports.
Resource and Extension Definitions
Following FHIR protocol, we propose three new FHIR resource and extension definitions for variant data: the Sequence resource, to represent patient genetic information; the SequencingLab extension, to describe the sequencing technology used for sequence generation; and the GeneticObservation extension, to link a phenotype to variant data (Table 1) . These definitions are discussed further below:
• The Sequence resource represents the raw genetic information of a patient and contains information about the specific read given by a sequencer for amino acid, RNA, or DNA sequences. The resource definition is designed in an abstract, non-format-specific way, such that developers can focus on the genetics, rather than native file formats.
• The SequencingLab extension of the Procedure resource 12 is a container for holding results about the specific Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory or research laboratory used to sequence a patient's genome. It may be useful for clinical documentation (for keeping track of how each patient's genotypes were determined). Our extension definition links to GA4GH data repositories and currently allows developers a "back door" for utilizing raw sequencing files by incorporating references to GA4GH's DataSet API endpoint.
• The GeneticObservation extension of the Observation resource 13 provides information about a patient's phenotype and genotype relationship. It links a patient phenotype to a set of genotypephenotype relationships associated with that trait. As an example use case, one GeneticObservation resource may describe cancer risk, and clinicians can query that resource to discover patient variants that affect their risk. GeneticObservation supports both germline and somatic variants.
Full specification of the proposed resource and extensions may be found in Table 1 or on the SMART on FHIR Genomics website ( Table 2 ). Figure 1 illustrates the relationships among the defined resources in a typical use case.
RESULTS
Figure 2 depicts one type of data coordination to feed a clinicogenomic app using SMART on FHIR augmented with SMART on FHIR Genomics. In such an app, clinical data from an EHR system is combined with genomics data from sequencing systems, all via SMART-standardized API calls. An app might identify, for example, an unidentified clinical problem using variant data for that patient. A different app might tap a gene-drug interaction database to propose or contraindicate certain drug therapies.
In practice, we refined SMART on FHIR Genomics by working with outside app developers with no a priori knowledge of SMART or FHIR. One group consisted of undergraduate students from universities unaffiliated with the authors of this paper. A second group consisted of a team of professional programmers at Vanderbilt University Medical Center. Both groups successfully developed useful clinico-genomics apps within a short timeframe. Based on their testing and our own, we iteratively refined the three SMART on FHIR Genomics definitions. With additional refinements, we believe our design could be offered for eventual HL7 balloting for a later release of FHIR. In the meantime, we have been providing input to the HL7 Clinical Genomics Workgroup and FHIR Management Group. Figure 3 depicts three clinico-genomic apps that leverage SMART on FHIR and SMART on FHIR Genomics. These apps access, calculate, and present CDS and other types of patient information in the areas of diabetes, genetic risk, and cancer diagnosis. For more information, please visit the links located in Table 2 .
DISCUSSION
The medical research community has increasingly recognized that creating "omics" data standards is problematic. 6 Tenenbaum et al. 6 presented a vision of "a standards-compliant, integrated data repository for clinical and 'omics' data, among other types," but believed that achieving this vision would be very difficult. They posited, moreover, that data standards would work best if they were concealed from researchers and that software developers, medical informaticists, and data curators, perhaps, would be "better equipped to delve into data standards than would be a clinician or bench scientist, but even they are typically not experts in specialized standards." 6 The SMART on FHIR Genomics specification demonstrates how it is possible to chip away at "the omics challenge." Our prototype apps demonstrate how a wide range of clinico-genomics use cases can be covered by our API. Moreover, the developer learning curve for SMART on FHIR Genomics proved very shallow: inexperience in working with genomic data could be overcome during a connectathon, suggesting that concerns about complexity can easily be addressed. Finally, we tested the feasibility of building SMART on FHIR Genomics data source adaptors by prototyping adaptors for Illumina, 23andMe, and the Vanderbilt Research Derivative. 14 Our preliminary efforts should encourage vendors that adaptor creation will not require a significant software engineering endeavor. Synergies are possible using enterprise clinical rules service (ECRS) for scalable clinical decision support. 15 In addition, new standards for extracting phenotypic information from unstructured EHRs 16 may enable linking genetic information to contexts outside of structured data. In short, we believe that the current specification of SMART on FHIR Genomics would hit the trifecta of sequencing data vendors, EHR vendors, and clinical app developers.
BRIEF COMMUNICATION
The FHIR standard was designed to create resource definitions for the most common medical scenarios. As of early 2015, there are 99 defined FHIR resources. It is our belief that genomics data are sufficiently distinct from existing FHIR resources to warrant a new resource and two GeneticObservations B is related to the variants in Sequence C, while GeneticObservation C describes a trait affected by a somatic mutation that is not linked to the germline sequence. Sequence A was determined at SequencingLab A, while Sequences B and C come from SequencingLab B. All eight resources are linked to the patient record, which is linked to additional clinical data (see Figure 2 ).
Figure 2:
A combination of SMART on FHIR for clinical data and SMART on FHIR Genomics for genomic data would enable standardized support for clinico-genomic apps. Data adaptors must be individually implemented for each source system. App developers would use the SMART on FHIR API exclusively to query and receive (or send) payloads from/to these "black box" systems. In this example, two genomic variant data sources are joined with a patient's clinical data. If sequence data are directly accessible via an EHR system (a rarity today), the SMART on FHIR Genomics Adaptor would be implemented against that EHR system.
extensions to the existing FHIR standard. While extensions can be created ad infinitum, a resource would have to be added to the central FHIR specification, which has a planned cap of 150 resources (personal communication, Lloyd McKenzie). Given that personalized medicine is rapidly becoming necessary for improved medical care, and given that patient sequencing data are already produced routinely by sequencing vendors, there is a compelling case for the HL7 community to engage, refine, and incorporate SMART on FHIR Genomics into FHIR. The HL7 Clinical Genomics Workgroup (of which two authors are co-chairs) recently voted to take portions of SMART on FHIR Genomics forward by incorporating those parts into a clinical genomics observation profile for FHIR DSTU2, which is currently in an HL7 ballot (see Table 1 ). Finally, the timing of advancing the results of this effort could not be better. As of this writing, FHIR is getting industry attention and input as it moves from DSTU1 to balloting for DSTU2. A broad coalition of industry and academic partners have recently formed the Health Services Platform Consortium and the Argonaut Project to advance, among other things, the SMART on FHIR framework for traditional clinical data and interoperability. CMS and the Office of the National Coordinator have continued to make interoperability a key focus of policy and funding. Finally, President Barack Obama announced the Precision Medicine Initiative during the 2015 State of the Union. 17 As the requirements for this initiative become clearer, we would expect that standard data frameworks for genetic variant data would come to the forefront as important tools for meeting those requirements. In this way, SMART on FHIR Genomics could be very beneficial.
CONCLUSION
SMART on FHIR Genomics describes a set of genomic data variant resource definitions and profile extensions compatible with FHIR. Designed to be part of the SMART on FHIR framework, the SMART on FHIR Genomics specification provides developers with a unified framework to tap multiple sources of genomic and EHR clinical data and create the type of apps that will be needed for precision medicine. Our genomics data specification has been tested and found to be capable of supporting high functioning clinico-genomics apps, and the feasibility of our endeavor has been verified by the creation of prototype Figure 3 : This figure depicts SMART on FHIR Genomics apps (projects.iq.harvard.edu/smartgenomics). The DB EMR (Diabetes Electronic Medical Record) app (A) integrates clinical, genomic, and sensor information. The Genomics Advisor app (B) presents estimates of disease risk based on germline Single Nucleotide Polymorphisms (SNPs) and operates alone or embedded in another app (as shown here). The Precision Cancer Medicine (PCM) app (C) integrates cancer genomic and clinical information to compare a patient to others with similar phenotypes and genotypes. PCM is a point-of-care mobile app that integrates a patient's clinical and somatic mutation data and is intended to aid physician-patient communication.
adaptors with common genomics data sources. In short, we tested a way to successfully provide standardized data access to genomic data. Moreover, we made that means of standardized access part of a larger, unifying approach to EHR clinical data and app development.
Combining SMART on FHIR Genomics and SMART on FHIR should yield impressive benefits for real-world stakeholders. DNA sequencing systems can deliver more value by offering a standard way to integrate gene and variant data with EHR system data (and vice versa). 18 Standardization ensures that clinical app developers can build and deploy powerful medical apps better, faster, and cheaper. Finally, providers can hope to obtain workflow-integrated, genomics-enriched CDS for their clinical staff that will help usher in the era of precision medical care.
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